No Data
Catalent's Maselli to Continue as CEO Post Novo Holdings Deal Close
Novo Nordisk's Oral Cardiovascular Drug Trial Achieves Primary Objective
Express News | 'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
Novo Nordisk Says European Medicines Agency Recommends Approval of Hemophilia Treatment
The Bunny Trader : nuclear energy :
Bull X Bear OP The Bunny Trader : I will add Nuclear as well